Publisher's Synopsis
Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Pravastatin Editorial: "A more benevolent prevention strategy, which deals with the totality of an individual's risk, yet deploys expensive drugs more liberally at lower doses than required to achieve guideline target lipid values, will save more lives." Disease Overview: "Raised cholesterol, in particular low density lipoprotein cholesterol (LDL-C), appears to be a pivotal risk factor in the development of coronary heart disease (CHD)." Drug Review: "Pravastatin treatment significantly reduced the relative risk of coronary events in younger and older patients, men and women, smokers and non-smokers, and patients with or without diabetes or hypertension." Improving Practice: "The burden of cardiovascular disease in the UK is large and is likely to increase as the population ages. At current rates, nearly half the population will die from a cardiovascular cause and so the problem impacts on all healthcare professionals."
